The point estimate indicated little to no evidence of a difference, with only a slight trend toward increased CMV risk with belatacept.
← all excerpts
Cytomegalovirus and BK polyomavirus in belatacept-treated kidney transplant recipients: a systematic review and meta-analysis.
1
—
—